Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07463521 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

Study acronym: MyVision
StatusRecruiting
PhasePhase 3
Started2026-05-27
View on ClinicalTrials.gov ↗

Amendment history

2026-09-10
Study Status, Contacts/Locations v4
Trial sites expanded: 11 → 14 locations
Trial sites expanded: 7 → 11 locations
2026-08-20
Study Identification, Study Status, Contacts/Locations v3
Trial sites expanded: 2 → 7 locations
2026-06-12
Study Status, Contacts/Locations v2
Recruitment opened
Start dateestimated 2026-05-29→confirmed 2026-05-27
Study sites0→2
2026-03-13
Study Identification, Study Status v1
Study titlerevised
A Study to Evaluate the Efficacy and Safety of RozanoloxizumabRozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
2026-03-05
Original filing
The purpose of the study is to demonstrate the efficacy, safety and tolerability of rozanolixizumab compared with placebo in the treatment of adult study participants with Ocular Myasthenia Gravis.
Trial Details
NCT Number NCT07463521
Lead Sponsor UCB Biopharma SRL
Conditions Ocular Myasthenia Gravis
Enrollment 120 participants
Start Date 2026-05-27
Primary Completion 2028-12-01 (estimated)
Study Completion 2029-01-22 (estimated)
Updated on ClinicalTrials.gov 2026-09-25